Ischemic StrokePhase 1RICE PACNCT03152799
Remote Ischaemic Conditioning in Endovascular Recanalization for Proximal Anterior Circulation Occlusion Study
A Phase 1 study testing RIPC Remote Ischaemic Pre-Conditioning in people with Ischemic Stroke, run by University College, London.
Trial summary
Ischaemic stroke causes significant morbidity and mortality and is a leading cause of disability within an ageing United Kingdom (UK) population. Proximal anterior circulation occlusion is associated with a particularly poor prognosis, but its management has undergone a paradigm shift following clinical introduction… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Ischemic Stroke
- What is being tested?
- RIPC Remote Ischaemic Pre-Conditioning
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- No sites listed yet
- Study dates
- 1 Aug 2017to 31 Dec 2019
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Acute, symptomatic proximal anterior circulation occlusion
- able to commence remote ischaemic conditioning within 6h of symptom onset
- identified as candidate for endovascular intervention according to local criteria
Who cannot join
- Age < 18 years
- Coagulopathy; International Normalised Ratio (INR) >2, alteplase dose > 90mg or 0.9mg/kg; platelet count < 50 x 10^9/L
- pregnancy
- BP >= 185/110 despite therapeutic intervention
- medical illness which interferes with outcome assessments (disability from other neurological disease)
- dependent on others for activities of daily living (ADLs) prior to current stroke (mRS modified Rankin Score was 3 - 5).
Show all 9Show fewer
- unlikely to be able to participate in study follow-up procedures (lives > 100 miles away; no fixed abode)
- already enrolled in another clinical trial involving investigational medicinal product or device
- baseline scan demonstrating significant prior infarction in the affected Middle Cerebral Artery (MCA) territory or an infarct that exceeds > 1/3 MCA territory
Trial locations and contacts
No sites are listed yet.
About this study
Official title: Remote Ischaemic Conditioning in Endovascular Recanalization for Proximal Anterior Circulation Occlusion (RICE PAC) Study
Ischaemic stroke causes significant morbidity and mortality and is a leading cause of disability within an ageing United Kingdom (UK) population. Proximal anterior circulation occlusion is associated with a particularly poor prognosis, but its management has undergone a paradigm shift following clinical introduction of endovascular recanalization, establishing rapid reperfusion of the ischaemic penumbra.
Remote ischaemic conditioning (RIC) is highly effective at attenuating cerebral infarction in basic research studies and has the potential to further improve patient outcome if used as an adjunct to invasive revascularisation strategies. We aim to trial remote ischaemic conditioning at the time of revascularisation, and then daily for the duration of the seven-day in-patient stay, compared to a sham conditioning procedure. This pilot, single-centre study will determine efficacy/ tolerability of RIC to reduce cerebral infarction (primary endpoint: determined by brain magnetic resonance imaging [MRI]) and improve functional status (secondary end-points: National Institutes of Health Stroke Severity (NIHSS); European Quality of Life questionnaire EurQoL), with the data providing the necessary parameters for power calculations and leveraging charitable funding for a subsequent multi-centre study.
Read the detailed description
The aims of our study are to:
- Demonstrate safety of remote ischaemic conditioning (RIC) in stroke patients;
- Demonstrate practicality of the intervention (RIC);
- Demonstrate the practicality of the study protocol and imaging modalities;
- Determining appropriate and measurable end-points: e.g. cerebral infarct reduction (MRI), reduction of cerebral oedema, functional assessment and quality of life survey;
- Provide preliminary data on likely effect size of the RIC intervention versus the sham procedure.
Background and Rationale:
Acute ischaemic stroke represents a significant cause of morbidity and mortality in the UK. It is estimated that 110,000 strokes occur in England each year, with an incidence of between 1-36/1000/year. Patients presenting with a proximal vessel occlusion in the anterior circulation have a particularly poor prognosis, with approximately 20% 90-day mortality and significant morbidity despite thrombolysis. Recently, endovascular recanalization with mechanical thrombectomy trials have brought about a paradigm shift in the optimal management of this high-risk group of patients; the interventional extraction of the occluding thrombus demonstrating significant benefits in MR-CLEAN(3), ESCAPE, EXTEND-IA (intra-arterial), SWIFT PRIME and REVASCAT (revascularisation) studies. Echoing primary percutaneous intervention in the management of ST-elevation myocardial infarction, endovascular recanalization represents rapid restoration of blood flow to the ischaemic cerebrum - with the promise of improved neurological salvage and functional outcome.
Reperfusion Injury:
Reperfusion is not, however, a benign process. Demonstrable in many organ systems including the brain (but studied most extensively in the heart), reperfusion leads to rapid restoration of intracellular pH, mitochondrial calcium overload and generation of reactive oxygen species - conditions that are prime for the opening of the mitochondrial permeability transition pore (mPTP). The mPTP, a large capacitance pore that forms on the inner mitochondrial membrane, leads to mitochondrial disruption and the release of proteins that trigger cell death. Therefore modifying conditions of reperfusion/ triggering cellular protection pathways are the key targets for optimising tissue salvage associated with reperfusion following any acute revascularisation intervention.
Remote ischaemic conditioning:
The brain has been demonstrated to share many of the cytoprotective signalling pathways found in other organs such as the heart, and like the heart, can be protected by ischaemic conditioning(6). Ischaemic conditioning can be either applied either directly to the organ, or more conveniently to a remote tissue (such as an arm, through inflation of a blood pressure cuff), either prior to, during or immediately following the restoration of blood flow to the ischaemic tissue (pre-, peri- and post-conditioning respectively). The remote conditioning stimulus leads to the activation of cellular survival kinases (termed the reperfusion injury salvage kinase (RISK) cascade) that in turn leads to inhibition of mPTP opening, and thus cell survival.
Ischaemic conditioning and neuro-protection:
While the phenomenon of ischaemic conditioning was first described and best characterised in the heart, it is well recognised that the ischaemic conditioning can result in cytoprotection across many mammalian organs, including the brain. Indeed, contemporaneous with the seminal myocardial preconditioning paper by Reimer, Murray and Jennings in the dog, Schurr et al demonstrated ischaemic preconditioning could also protect adult rat hippocampal slices against injurious anoxia/re-oxygenation. Ischaemic conditioning of neuronal tissue has subsequently been demonstrated to be triggered and mediated by similar receptor and downstream signalling pathways (e.g. G-protein coupled receptors, RISK pathway activation and suppression of cell death pathways), and that remote ischaemic conditioning is also effective at significantly attenuating the volume of cerebral necrosis in rat experimental models of acute right middle cerebral artery occlusion stroke (typically reducing infarct size by 40-60%). Similar results are observed in mouse (middle cerebral embolization, followed by thrombolysis with tissue-plasminogen activator) and in piglet, where the injurious effects of hypothermic circulatory arrest were attenuated, improving both functional and histological outcomes.
With building evidence of efficacy against cerebral ischaemia/reperfusion injury in the pre-clinical basic science studies, there is enthusiasm to translate these encouraging data into an effective clinical strategy for the management of acute stroke in man. A recent prospective, open-label, blinded outcome proof-of-concept study in Danish patients undertook ischaemic per-conditioning in patients presenting with an acute stroke syndrome. With the conditioning stimulus performed in the ambulance, the ischaemic stroke diagnosis was made/confirmed later in hospital. In patients with confirmed ischaemic stroke, they found patients in the intervention arm had a better functional status by National Institutes of Health Stroke Scale score on admission and an overall smaller infarct, but the study was overall neutral on the pre-specified primary endpoint (penumbral salvage, defined as the volume of the perfusion-diffusion mismatch not progressing to infarction after 1 month). There are useful lessons and observations to be made regarding the design of this trial that influences the design of the trial proposed within this application. First, thrombolysis does not guarantee re-canalisation of the culprit artery, and where restoration of blood flow does occur, the time of onset of reperfusion may be unpredictable. Thus, restoration of blood flow may either not have occurred, or when it had, may have occurred outside the protective time-frame of the remote ischaemic conditioning stimulus (classical conditioning has a protective "window" of typically just 2-3 hours).
Therefore, we are seeking to combine ischaemic conditioning with an effective endovascular re-canalisation procedure where the success and time of reperfusion are known. Second, in the Danish study, there would have been significant heterogeneity in aetiology of the presenting stroke symptoms that will include both anterior and posterior circulation occlusion and also small vessel disease. The pre-clinical efficacy of remote ischaemic conditioning is predominantly with models of anterior circulation occlusion and therefore, we have made this cohort of patients the focus of our study. And finally, there is emerging evidence that in order to ensure persistent infarct size reduction, it is critical to combine both initial ischaemic per-conditioning and subsequent post-conditioning to tackle both the acute reperfusion injury (the first 15 minutes of reperfusion) and the subsequent second phase of reperfusion injury (that occurs in the following hours and days). Thus our study is designed to combine both ischaemic per-conditioning and repeated post-conditioning over the following seven days to harvest the benefit of both conditioning strategies.
Interestingly, a Chinese study (RIC to both arms daily for 300 days after the initial stroke) was shown to be safe and effective. While this study had a different outcome to ours (attenuating the rate of stroke recurrence following the initial presentation), the efficacy of the RIC intervention nonetheless provides further encouragement that RIC may be an effective intervention in this group of patients.
In summary therefore, we are seeking to combine ischaemic conditioning with an effective endovascular re-canalisation procedure where the success and time of reperfusion are known, in a vascular territory that is known to benefit from RIC and are looking to combine both ischaemic per-conditioning and repeated post-conditioning over the following seven days to harvest the benefit of both conditioning strategies upon acute and inflammatory phases of reperfusion injury - encompassing the period over which peak cerebral oedema is typically observed.
- Conditions
- Ischemic Stroke
- Being tested
- RIPC Remote Ischaemic Pre-Conditioning, Sham Control
- Keywords
- remote ischaemic conditioning, remote ischemic conditioning, cerebral infarction, ischaemia reperfusion injury, ischemia reperfusion injury, anterior circulation stroke, mechanical thrombectomy
- Medical subject headings
- Ischemic Stroke, Cerebral Infarction, Reperfusion Injury
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RIPC Remote Ischaemic Pre-ConditioningProcedure or surgery
Also called Remote Ischaemic PreConditioning
intermittent limb ischaemia via a peripheral blood pressure cuff inflation and deflation
Sham ControlOther
intermittent peripheral blood pressure cuff inflation and deflation which does not induce a protective cellular response
| Study group | Role | What they receive |
|---|---|---|
| Remote Ischaemic Pre-Conditioning (RIPC) Intervention | Experimental | Remote Ischaemic Pre-Conditioning intervention to be applied via peripheral blood pressure cuff inflation/deflations to upper lower limb contra-lateral to affected side of hemiparesis Receives: Procedure: RIPC Remote Ischaemic Pre-Conditioning |
| Sham Control | Sham comparator | Sham Control to be applied via peripheral blood pressure cuff inflation/deflations to upper lower limb contra-lateral to affected side of hemiparesis Receives: Other: Sham Control |
What is being measured
The primary outcome is the main question the study is designed to answer.
reduction of infarct size as proportion of ischaemic penumbra following revascularisation
Proportion of ischaemic penumbra determined by MRI at 3 months post-revascularisation
Measured: 3 months after revascularisation / thrombectomy
Secondary outcomes (4)
Reduction of cerebral oedema and infarct size (second-phase reperfusion injury)
Proportion of ischaemic penumbra comparing MRI data at 24 hours and 7 days post-thrombectomy
Measured: MRI at 7 days post-thrombectomy
Neurological Recovery at 24 h and 3 months post-revascularisation
modified Rankin Score
Measured: at 24h hours and 3 months post-revascularisation
Neurological Recovery at 24 h and 3 months post-revascularisation
NIHSS (National Institutes of Health Stroke Scale)
Measured: at 24h hours and 3 months post-revascularisation
Neurological Recovery at 24 h and 3 months post-revascularisation
QoL (Quality of Life) assessment
Measured: at 24h hours and 3 months post-revascularisation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 May 2017
- Study start1 Aug 2017 (estimated)
- Primary completion1 Aug 2019 (estimated)
- Study completion31 Dec 2019 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (9)Papers the sponsor has linked to this study.
- Other trials for Ischemic StrokeStudies of the same condition, open and under way.
- More trials run by University College, LondonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Model description
- pilot, single-centre, double-blind, sham-controlled (non-clinical trial of investigational medicinal product \[non-CTIMP\]) study of repeated daily remote ischaemic conditioning vs placebo/sham in the context of acute anterior circulation stroke
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University College, London
- Sponsor type
- University, hospital or other
- Collaborators
- University College London Hospitals, National Hospital for Neurology and Neurosurgery
- Responsible party
- Sponsor
- Investigators
- Robert M Bell, PhD MRCP, Principal investigator, Hatter Cardiovascular Institute UCLDerek Yellon, PhD DSc, Study director, Hatter Cardiovascular Institute UCL
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03152799
- Sponsor's protocol ID
- 222254
- Acronym
- RICE PAC
- Status last verified
- May 2017
- First submitted
- 8 Mar 2017
- Last updated
- 15 May 2017
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Department of Health: Progress in Improving Stroke Care. In: Office NA, editor.: The Stationary Office; 2010.
Hippisley-Cox J, Pringle M, Ryan R. Stroke: Prevalence, Incidence and Care in General Practices 2002-2004. Final Report to the National Stroke Audit Team. In: Physicians RCo, editor. 2004.
Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, Schonewille WJ, Vos JA, Nederkoorn PJ, Wermer MJ, van Walderveen MA, Staals J, Hofmeijer J, van Oostayen JA, Lycklama a Nijeholt GJ, Boiten J, Brouwer PA, Emmer BJ, de Bruijn SF, van Dijk LC, Kappelle LJ, Lo RH, van Dijk EJ, de Vries J, de Kort PL, van Rooij WJ, van den Berg JS, van Hasselt BA, Aerden LA, Dallinga RJ, Visser MC, Bot JC, Vroomen PC, Eshghi O, Schreuder TH, Heijboer RJ, Keizer K, Tielbeek AV, den Hertog HM, Gerrits DG, van den Berg-Vos RM, Karas GB, Steyerberg EW, Flach HZ, Marquering HA, Sprengers ME, Jenniskens SF, Beenen LF, van den Berg R, Koudstaal PJ, van Zwam WH, Roos YB, van der Lugt A, van Oostenbrugge RJ, Majoie CB, Dippel DW; MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015 Jan 1;372(1):11-20. doi: 10.1056/NEJMoa1411587. Epub 2014 Dec 17.
PubMed 25517348Moore JM, Griessenauer CJ, Gupta R, Adeeb N, Patel AS, Ogilvy CS, Thomas AJ. Landmark papers in cerebrovascular neurosurgery 2015. Clin Neurol Neurosurg. 2016 Sep;148:22-8. doi: 10.1016/j.clineuro.2016.06.007. Epub 2016 Jun 18.
PubMed 27366977Bell RM, Yellon DM. There is more to life than revascularization: therapeutic targeting of myocardial ischemia/reperfusion injury. Cardiovasc Ther. 2011 Dec;29(6):e67-79. doi: 10.1111/j.1755-5922.2010.00190.x. Epub 2010 Jul 14.
PubMed 20645988Hahn CD, Manlhiot C, Schmidt MR, Nielsen TT, Redington AN. Remote ischemic per-conditioning: a novel therapy for acute stroke? Stroke. 2011 Oct;42(10):2960-2. doi: 10.1161/STROKEAHA.111.622340. Epub 2011 Aug 11.
PubMed 21836089Hougaard KD, Hjort N, Zeidler D, Sorensen L, Norgaard A, Hansen TM, von Weitzel-Mudersbach P, Simonsen CZ, Damgaard D, Gottrup H, Svendsen K, Rasmussen PV, Ribe LR, Mikkelsen IK, Nagenthiraja K, Cho TH, Redington AN, Botker HE, Ostergaard L, Mouridsen K, Andersen G. Remote ischemic perconditioning as an adjunct therapy to thrombolysis in patients with acute ischemic stroke: a randomized trial. Stroke. 2014 Jan;45(1):159-67. doi: 10.1161/STROKEAHA.113.001346. Epub 2013 Nov 7.
PubMed 24203849Ren C, Wang P, Wang B, Li N, Li W, Zhang C, Jin K, Ji X. Limb remote ischemic per-conditioning in combination with post-conditioning reduces brain damage and promotes neuroglobin expression in the rat brain after ischemic stroke. Restor Neurol Neurosci. 2015;33(3):369-79. doi: 10.3233/RNN-140413.
PubMed 25868435Meng R, Asmaro K, Meng L, Liu Y, Ma C, Xi C, Li G, Ren C, Luo Y, Ling F, Jia J, Hua Y, Wang X, Ding Y, Lo EH, Ji X. Upper limb ischemic preconditioning prevents recurrent stroke in intracranial arterial stenosis. Neurology. 2012 Oct 30;79(18):1853-61. doi: 10.1212/WNL.0b013e318271f76a. Epub 2012 Oct 3.
PubMed 23035060
Study at a glance
From the registry record, last updated by the sponsor on 15 May 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Remote Ischaemic Conditioning in Endovascular Recanalization for Proximal Anterior Circulation Occlusion (RICE PAC) Study
- ClinicalTrials.gov ID
- NCT03152799
- Acronym / sponsor ID
- RICE PAC / 222254
- Conditions
- Ischemic Stroke
- Keywords
- remote ischaemic conditioning, remote ischemic conditioning, cerebral infarction, ischaemia reperfusion injury, ischemia reperfusion injury, anterior circulation stroke, mechanical thrombectomy
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- University College, LondonUniversity, hospital or other
- Collaborators
- University College London Hospitals, National Hospital for Neurology and Neurosurgery
- Study start
- 1 Aug 2017 (estimated)
- Primary completion
- 1 Aug 2019 (estimated)
- Study completion
- 31 Dec 2019 (estimated)
- First posted
- 15 May 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Ischaemic stroke causes significant morbidity and mortality and is a leading cause of disability within an ageing United Kingdom (UK) population. Proximal anterior circulation occlusion is associated with a particularly poor prognosis, but its management has undergone a paradigm shift following clinical introduction of endovascular recanalization, establishing rapid reperfusion of the ischaemic penumbra.
Remote ischaemic conditioning (RIC) is highly effective at attenuating cerebral infarction in basic research studies and has the potential to further improve patient outcome if used as an adjunct to invasive revascularisation strategies. We aim to trial remote ischaemic conditioning at the time of revascularisation, and then daily for the duration of the seven-day in-patient stay, compared to a sham conditioning procedure. This pilot, single-centre study will determine efficacy/ tolerability of RIC to reduce cerebral infarction (primary endpoint: determined by brain magnetic resonance imaging [MRI]) and improve functional status (secondary end-points: National Institutes of Health Stroke Severity (NIHSS); European Quality of Life questionnaire EurQoL), with the data providing the necessary parameters for power calculations and leveraging charitable funding for a subsequent multi-centre study.
Detailed description
The aims of our study are to:
- Demonstrate safety of remote ischaemic conditioning (RIC) in stroke patients;
- Demonstrate practicality of the intervention (RIC);
- Demonstrate the practicality of the study protocol and imaging modalities;
- Determining appropriate and measurable end-points: e.g. cerebral infarct reduction (MRI), reduction of cerebral oedema, functional assessment and quality of life survey;
- Provide preliminary data on likely effect size of the RIC intervention versus the sham procedure.
Background and Rationale:
Acute ischaemic stroke represents a significant cause of morbidity and mortality in the UK. It is estimated that 110,000 strokes occur in England each year, with an incidence of between 1-36/1000/year. Patients presenting with a proximal vessel occlusion in the anterior circulation have a particularly poor prognosis, with approximately 20% 90-day mortality and significant morbidity despite thrombolysis. Recently, endovascular recanalization with mechanical thrombectomy trials have brought about a paradigm shift in the optimal management of this high-risk group of patients; the interventional extraction of the occluding thrombus demonstrating significant benefits in MR-CLEAN(3), ESCAPE, EXTEND-IA (intra-arterial), SWIFT PRIME and REVASCAT (revascularisation) studies. Echoing primary percutaneous intervention in the management of ST-elevation myocardial infarction, endovascular recanalization represents rapid restoration of blood flow to the ischaemic cerebrum - with the promise of improved neurological salvage and functional outcome.
Reperfusion Injury:
Reperfusion is not, however, a benign process. Demonstrable in many organ systems including the brain (but studied most extensively in the heart), reperfusion leads to rapid restoration of intracellular pH, mitochondrial calcium overload and generation of reactive oxygen species - conditions that are prime for the opening of the mitochondrial permeability transition pore (mPTP). The mPTP, a large capacitance pore that forms on the inner mitochondrial membrane, leads to mitochondrial disruption and the release of proteins that trigger cell death. Therefore modifying conditions of reperfusion/ triggering cellular protection pathways are the key targets for optimising tissue salvage associated with reperfusion following any acute revascularisation intervention.
Remote ischaemic conditioning:
The brain has been demonstrated to share many of the cytoprotective signalling pathways found in other organs such as the heart, and like the heart, can be protected by ischaemic conditioning(6). Ischaemic conditioning can be either applied either directly to the organ, or more conveniently to a remote tissue (such as an arm, through inflation of a blood pressure cuff), either prior to, during or immediately following the restoration of blood flow to the ischaemic tissue (pre-, peri- and post-conditioning respectively). The remote conditioning stimulus leads to the activation of cellular survival kinases (termed the reperfusion injury salvage kinase (RISK) cascade) that in turn leads to inhibition of mPTP opening, and thus cell survival.
Ischaemic conditioning and neuro-protection:
While the phenomenon of ischaemic conditioning was first described and best characterised in the heart, it is well recognised that the ischaemic conditioning can result in cytoprotection across many mammalian organs, including the brain. Indeed, contemporaneous with the seminal myocardial preconditioning paper by Reimer, Murray and Jennings in the dog, Schurr et al demonstrated ischaemic preconditioning could also protect adult rat hippocampal slices against injurious anoxia/re-oxygenation. Ischaemic conditioning of neuronal tissue has subsequently been demonstrated to be triggered and mediated by similar receptor and downstream signalling pathways (e.g. G-protein coupled receptors, RISK pathway activation and suppression of cell death pathways), and that remote ischaemic conditioning is also effective at significantly attenuating the volume of cerebral necrosis in rat experimental models of acute right middle cerebral artery occlusion stroke (typically reducing infarct size by 40-60%). Similar results are observed in mouse (middle cerebral embolization, followed by thrombolysis with tissue-plasminogen activator) and in piglet, where the injurious effects of hypothermic circulatory arrest were attenuated, improving both functional and histological outcomes.
With building evidence of efficacy against cerebral ischaemia/reperfusion injury in the pre-clinical basic science studies, there is enthusiasm to translate these encouraging data into an effective clinical strategy for the management of acute stroke in man. A recent prospective, open-label, blinded outcome proof-of-concept study in Danish patients undertook ischaemic per-conditioning in patients presenting with an acute stroke syndrome. With the conditioning stimulus performed in the ambulance, the ischaemic stroke diagnosis was made/confirmed later in hospital. In patients with confirmed ischaemic stroke, they found patients in the intervention arm had a better functional status by National Institutes of Health Stroke Scale score on admission and an overall smaller infarct, but the study was overall neutral on the pre-specified primary endpoint (penumbral salvage, defined as the volume of the perfusion-diffusion mismatch not progressing to infarction after 1 month). There are useful lessons and observations to be made regarding the design of this trial that influences the design of the trial proposed within this application. First, thrombolysis does not guarantee re-canalisation of the culprit artery, and where restoration of blood flow does occur, the time of onset of reperfusion may be unpredictable. Thus, restoration of blood flow may either not have occurred, or when it had, may have occurred outside the protective time-frame of the remote ischaemic conditioning stimulus (classical conditioning has a protective "window" of typically just 2-3 hours).
Therefore, we are seeking to combine ischaemic conditioning with an effective endovascular re-canalisation procedure where the success and time of reperfusion are known. Second, in the Danish study, there would have been significant heterogeneity in aetiology of the presenting stroke symptoms that will include both anterior and posterior circulation occlusion and also small vessel disease. The pre-clinical efficacy of remote ischaemic conditioning is predominantly with models of anterior circulation occlusion and therefore, we have made this cohort of patients the focus of our study. And finally, there is emerging evidence that in order to ensure persistent infarct size reduction, it is critical to combine both initial ischaemic per-conditioning and subsequent post-conditioning to tackle both the acute reperfusion injury (the first 15 minutes of reperfusion) and the subsequent second phase of reperfusion injury (that occurs in the following hours and days). Thus our study is designed to combine both ischaemic per-conditioning and repeated post-conditioning over the following seven days to harvest the benefit of both conditioning strategies.
Interestingly, a Chinese study (RIC to both arms daily for 300 days after the initial stroke) was shown to be safe and effective. While this study had a different outcome to ours (attenuating the rate of stroke recurrence following the initial presentation), the efficacy of the RIC intervention nonetheless provides further encouragement that RIC may be an effective intervention in this group of patients.
In summary therefore, we are seeking to combine ischaemic conditioning with an effective endovascular re-canalisation procedure where the success and time of reperfusion are known, in a vascular territory that is known to benefit from RIC and are looking to combine both ischaemic per-conditioning and repeated post-conditioning over the following seven days to harvest the benefit of both conditioning strategies upon acute and inflammatory phases of reperfusion injury - encompassing the period over which peak cerebral oedema is typically observed.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- pilot, single-centre, double-blind, sham-controlled (non-clinical trial of investigational medicinal product [non-CTIMP]) study of repeated daily remote ischaemic conditioning vs placebo/sham in the context of acute anterior circulation stroke
| Arm | Type | Receives |
|---|---|---|
| Remote Ischaemic Pre-Conditioning (RIPC) Intervention | Experimental | Procedure: RIPC Remote Ischaemic Pre-ConditioningRemote Ischaemic Pre-Conditioning intervention to be applied via peripheral blood pressure cuff inflation/deflations to upper lower limb contra-lateral to affected side of hemiparesis |
| Sham Control | Sham comparator | Other: Sham ControlSham Control to be applied via peripheral blood pressure cuff inflation/deflations to upper lower limb contra-lateral to affected side of hemiparesis |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Acute, symptomatic proximal anterior circulation occlusion
- able to commence remote ischaemic conditioning within 6h of symptom onset
- identified as candidate for endovascular intervention according to local criteria
Key exclusion criteria (9 listed)
- Age < 18 years
- Coagulopathy; International Normalised Ratio (INR) >2, alteplase dose > 90mg or 0.9mg/kg; platelet count < 50 x 10^9/L
- pregnancy
- BP >= 185/110 despite therapeutic intervention
- medical illness which interferes with outcome assessments (disability from other neurological disease)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RIPC Remote Ischaemic Pre-ConditioningAlso: Remote Ischaemic PreConditioningintermittent limb ischaemia via a peripheral blood pressure cuff inflation and deflation | Procedure or surgery | Remote Ischaemic Pre-Conditioning (RIPC) Intervention |
| Sham Controlintermittent peripheral blood pressure cuff inflation and deflation which does not induce a protective cellular response | Other | Sham Control |
Primary outcome
reduction of infarct size as proportion of ischaemic penumbra following revascularisation
Time frame: 3 months after revascularisation / thrombectomy
Proportion of ischaemic penumbra determined by MRI at 3 months post-revascularisation
4 secondary outcomes
Reduction of cerebral oedema and infarct size (second-phase reperfusion injury)
Time frame: MRI at 7 days post-thrombectomy
Neurological Recovery at 24 h and 3 months post-revascularisation
Time frame: at 24h hours and 3 months post-revascularisation
Neurological Recovery at 24 h and 3 months post-revascularisation
Time frame: at 24h hours and 3 months post-revascularisation
Neurological Recovery at 24 h and 3 months post-revascularisation
Time frame: at 24h hours and 3 months post-revascularisation
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 May 2017.
- BackgroundDepartment of Health: Progress in Improving Stroke Care. In: Office NA, editor.: The Stationary Office; 2010.
- BackgroundHippisley-Cox J, Pringle M, Ryan R. Stroke: Prevalence, Incidence and Care in General Practices 2002-2004. Final Report to the National Stroke Audit Team. In: Physicians RCo, editor. 2004.
- Background: PubMed 25517348Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, Schonewille WJ, Vos JA, Nederkoorn PJ, Wermer MJ, van Walderveen MA, Staals J, Hofmeijer J, van Oostayen JA, Lycklama a Nijeholt GJ, Boiten J, Brouwer PA, Emmer BJ, de Bruijn SF, van Dijk LC, Kappelle LJ, Lo RH, van Dijk EJ, de Vries J, de Kort PL, van Rooij WJ, van den Berg JS, van Hasselt BA, Aerden LA, Dallinga RJ, Visser MC, Bot JC, Vroomen PC, Eshghi O, Schreuder TH, Heijboer RJ, Keizer K, Tielbeek AV, den Hertog HM, Gerrits DG, van den Berg-Vos RM, Karas GB, Steyerberg EW, Flach HZ, Marquering HA, Sprengers ME, Jenniskens SF, Beenen LF, van den Berg R, Koudstaal PJ, van Zwam WH, Roos YB, van der Lugt A, van Oostenbrugge RJ, Majoie CB, Dippel DW; MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015 Jan 1;372(1):11-20. doi: 10.1056/NEJMoa1411587. Epub 2014 Dec 17.
- Background: PubMed 27366977Moore JM, Griessenauer CJ, Gupta R, Adeeb N, Patel AS, Ogilvy CS, Thomas AJ. Landmark papers in cerebrovascular neurosurgery 2015. Clin Neurol Neurosurg. 2016 Sep;148:22-8. doi: 10.1016/j.clineuro.2016.06.007. Epub 2016 Jun 18.
- Background: PubMed 20645988Bell RM, Yellon DM. There is more to life than revascularization: therapeutic targeting of myocardial ischemia/reperfusion injury. Cardiovasc Ther. 2011 Dec;29(6):e67-79. doi: 10.1111/j.1755-5922.2010.00190.x. Epub 2010 Jul 14.
- Background: PubMed 21836089Hahn CD, Manlhiot C, Schmidt MR, Nielsen TT, Redington AN. Remote ischemic per-conditioning: a novel therapy for acute stroke? Stroke. 2011 Oct;42(10):2960-2. doi: 10.1161/STROKEAHA.111.622340. Epub 2011 Aug 11.
- Background: PubMed 24203849Hougaard KD, Hjort N, Zeidler D, Sorensen L, Norgaard A, Hansen TM, von Weitzel-Mudersbach P, Simonsen CZ, Damgaard D, Gottrup H, Svendsen K, Rasmussen PV, Ribe LR, Mikkelsen IK, Nagenthiraja K, Cho TH, Redington AN, Botker HE, Ostergaard L, Mouridsen K, Andersen G. Remote ischemic perconditioning as an adjunct therapy to thrombolysis in patients with acute ischemic stroke: a randomized trial. Stroke. 2014 Jan;45(1):159-67. doi: 10.1161/STROKEAHA.113.001346. Epub 2013 Nov 7.
- Background: PubMed 25868435Ren C, Wang P, Wang B, Li N, Li W, Zhang C, Jin K, Ji X. Limb remote ischemic per-conditioning in combination with post-conditioning reduces brain damage and promotes neuroglobin expression in the rat brain after ischemic stroke. Restor Neurol Neurosci. 2015;33(3):369-79. doi: 10.3233/RNN-140413.
- Background: PubMed 23035060Meng R, Asmaro K, Meng L, Liu Y, Ma C, Xi C, Li G, Ren C, Luo Y, Ling F, Jia J, Hua Y, Wang X, Ding Y, Lo EH, Ji X. Upper limb ischemic preconditioning prevents recurrent stroke in intracranial arterial stenosis. Neurology. 2012 Oct 30;79(18):1853-61. doi: 10.1212/WNL.0b013e318271f76a. Epub 2012 Oct 3.
- Hatter Cardiovascular InstituteLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Ischemic Stroke
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
RecruitingObservational study
ELATE Study: Evaluating Large-vessel Acute Thrombectomy in Extended Time Window
Acute Ichemic Stroke
Not yet recruiting
Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
Acute Ischemic Stroke, Basilar Artery Occlusion
Active, not recruiting
Improving Visual Field Deficits With Noninvasive Brain Stimulation
Visual Field Defect, Peripheral, Stroke
Recruiting
Biomarkers of Paired VNS
Stroke, Ischemic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Robert M Bell, PhD MRCP principal investigator
Hatter Cardiovascular Institute UCL
Derek Yellon, PhD DSc study director
Hatter Cardiovascular Institute UCL
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing RIPC Remote Ischaemic Pre-Conditioning in people with Ischemic Stroke, run by University College, London.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 15 May 2017. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Richard Perry, PhD MRCP (020 3448 3416, richard.perry@uclh.nhs.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
reduction of infarct size as proportion of ischaemic penumbra following revascularisation (time frame: 3 months after revascularisation / thrombectomy). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03152799, which also lists 9 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2017.